Acta Endicronologica
RomanianAcademy Romanian Academy
The Publishing House of the Romanian Academy The Publishing House of the Romanian Academy

ACTA ENDOCRINOLOGICA (BUC)

The International Journal of Romanian Society of Endocrinology / Registered in 1938

in Web of Science Master Journal List

Acta Endocrinologica(Bucharest) is live in PubMed Central

Journal Impact Factor - click here.

Year Volume Issue First page
10.4183/aeb.
Author
Title
Abstract/Title
From through

  • Abstract view [Login to see FullText]

    General Endocrinology

    Rosianu A, Lazar E, Raica M

    Oncoprotein c-erb B2 - prognostic significance in invasive breast cancer

    Acta Endo (Buc) 2005 1(2): 145-156 doi: 10.4183/aeb.2005.145

    Abstract References
    Objective: The invasive mammary cancer is the most frequent malignant tumor of a woman. Among the potential prognostic factors are included the biomarkers which measure or are associated with biological processes involved in the tumoral progression.We studied the prognostic importance of the oncoprotein c-erbB2 in the invasive mammary cancer.\r\nMaterials and methods: We included in the study 56 female patients suffering from invasive mammary cancer.The tissue fragments were fitted in formol, included to paraffin, commonly stained with hematoxylin-eosine (HE); for the determination of the c-erbB2 we\r\nused the immunohistochemical method of the avidin-biotin (ABC) complex.\r\nResults: From the total of 56 tumors, 38 (67.9%) presented different degrees of positivity; 18 (32.1%) did not express the oncoprotein c-erbB2.\r\nConclusions: The positivity of oncoprotein c-erbB2 was correlated with the size of the tumor; the carcinomas which are not infiltrative ductal, known as having a better prognostic, were c-erbB2 negative.
    1. Hartmann Lynn, Ingle JN, Wold LE, Farr GH, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE and Roche PC. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Cancer 1994; 74(11): 2956-2962.
    2. Guerin M, Gabillot M, Mathieu MC et al. Structure and expression of c-erbB2 and EGFR receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int. J. Cancer 1989; 43: 201. [CrossRef]
    3. Gullik JW, Lowe SB, Wright C et al. c-erbB2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved nodes. Br. J. Cancer 1991; 63: 434-438. [CrossRef]
    4. Gusterson BA, Golber RD, Goldhirsch A, Prince KN, love Soderbergh J, Anboyhagen Ret. et al. Prognostic importance of c-erbB2 expression in breast cancer. J Clin Oncol. 1992;10:1049-1056.
    5. Paul P, Rosen MD, Martin L, Lesser Ph D, Crispinita D, Arrayo CLS et al.: Immunohistochemical detection of HER2/neu in patients with axillary lymph nodes negative breast carcinoma. Cancer 1995; 75(6):1320-1325. [CrossRef]
    6. Seshardi R, Firgaira FA, Horsfall DJ, Mc Caul K, Setur V, Vithen P. Clinical significance of HER2/neu oncogene amplificator in primary breast cancer. J. Clin. Oncol. 1993;11:1936-1946.
    7. Toikkanen S, Kujari H. Pure and mixed mucinous carcinomas of the breast: a clinicopathologic analysis of 61 cases with long term follow-up. Hum. Pathol. 1989;20:758-764. [CrossRef]
    8. Garcia I, Dietrich P, Aapro M, Vauthier G, Vadus L, and Engel E. Genetic alteration of c-myc, c-erbB2 and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res. 1989; 49:6675.
    9. Parkes HC, Lillycrop K, Howell A and Craig RK. c-erbB2 mRNA expression in human breast tumors: comparison with c-erbB2 DNA amplification and correlation with prognosis. Br. J. Cancer 1990;61: 39. [CrossRef]
    10. Perren TJ. c-erbB2 oncogene as a prognostic marker in breast cancer. Br. J. Cancer 1991; 63: 328- 332. [CrossRef]
    11. Silverberg G. Steven. Principles and practice of surgical pathology, vol I, 1983: 245, 266-267, 270- 295.
    12. Rosen PP, Martin L, Crispinita L, Arrayo D, Cranor M, Borgen P, Norton L. p53 in node negative breast carcinoma: an immunohistochemical study of epidemiologic risk factors, histologic features and prognosis. HJ. Clin Oncol. 1995; 13(4): 821-830.
    13. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707. [CrossRef]
    14. Van de Vivjer MJ, Peterse JL, Moori WJ, Wisman P, Lomans J, Dalesio O et al: HER2/neu protein overexpression in breast cancer: association with comedothipe ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N. Engl. J. Med.
    15. Wright C, Angus B, Nicholson S et al: Expression of c-erbB2 oncoprotein: a prognostic indicator in human breast cancer. Cancer Res. 1989; 49: 2087-2090.
    16. Lovekin C, Ellis JO, Lockr A et al. c-erbB2 oncoprotein expression in primary and advanced breast cancer. Br. J. Cancer 1991; 63:439. [CrossRef]
    17. Borg A, Tandon AK, Sigurdsson H et al. HER2/neu amplificattion predicts poor survival in nodepositive breast cancer. Cancer Res. 1990; 50:4332.
    18. Gasparini G, Dal Fior S, Pozza P, Bevilaqua P. Correlation of growth fraction by Ki-67 immunohistochemistry with histologic factors and hormone receptors in operable breast carcinoma. Breast Cancer Res. Treat. 1989; 14: 329-336. [CrossRef]
    19. Barnes DM, Lammine GA, Mollis RR, Gullik WL, Allen DS and Altman DG. An immunohistochemical evaluation of c-erbB2 expression in human breast carcinoma. Br. J. Cancer 1988; 58; 448. [CrossRef]
    20. Ro YJ, El Naggar A, Ro J et al. c-erbB2 amplification in node negative human breast cancer. Cancer Res. 1989; 49: 6941.
    21. May E, Mouriesse M, May-Levin F, Contesso G, and Delarue JC. A new approach allowing an early prognosis in breast cancer; a ratio of estrogen receptor (ER) ligand binding activity to the ERspecific mRNA level. Oncogene 1989; 4:1037.
    22. Adnane J, Guadray P, Simon MP, Simony-Lafontaine J, Jeanteur p and Theillet C. Proto-oncogene amplification and human breast tumor phenotype. Oncogene 1989; 4: 1389.
    23. Tetu B., Brisson J. Prognostic significance of HER2/neu oncoprotein expression in node-positive breast cancer: the influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994; 73: 2359. [CrossRef]
    24. Ravdin PM., Chamness GC.The c-erbB2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecule markers. Gene (in press).
    25. Fattaneh A, Tavassoli PD. Pathology and genetics of tumors of the breast and female genital organs. IARCPress, Lyon, 2003: 13-15.
  • Abstract view [Login to see FullText]

    Case Report

    Stoicanescu D, Belengeanu V, Amzar D, Popa C, Hrubaru N, Rosianu A

    Complete gonadal dysgenesis with XY chromosomal constitution

    Acta Endo (Buc) 2006 2(4): 465-470 doi: 10.4183/aeb.2006.465

    Abstract
    A 20-year-old woman was studied because of lack of spontaneous pubertal development and primary amenorrhea. At the moment of examination in the Medical Genetics Department she had normal height, sparse axillary and pubic hair, but breasts were well developed (she already had some estrogen therapy). She had normal but infantile external genitalia, normal vagina and small uterus. Laparoscopic investigation suggested the presence of gonadoblastoma in the dysgenetic gonads and histopathologic examination confirmed the diagnosis. The karyotype revealed a 46, XY chromosome constitution in lymphocytes, without structural defects of X or Y chromosomes. Because of the risk of malignancy, gonadectomy was performed.


ISSN (print): 1841 - 0987     ISSN (online): 1843 - 066X  
Cookie Policy    Privacy Policy

Soluționarea alternativă a litigiilor Soluționarea online a litigiilor